---
title: "Eli Lilly’s EloraTZP delivers up to 23.3% average weight loss in Phase 2 trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305552298.md"
description: "Eli Lilly will present Phase 2 results for its investigational obesity treatment EloraTZP at ObesityWeek 2026. The trial demonstrated up to 23.3% average weight loss and improved blood sugar control in adults with obesity or overweight and type 2 diabetes. Additionally, Phase 3 data for retatrutide showed reduced sleep apnea severity and knee osteoarthritis pain, while Zepbound significantly lowered BMI in adolescents with obesity."
datetime: "2026-11-14T17:01:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305552298.md)
  - [en](https://longbridge.com/en/news/305552298.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305552298.md)
generator: "portal-rs"
---

# Eli Lilly’s EloraTZP delivers up to 23.3% average weight loss in Phase 2 trial

-   Eli Lilly will present obesity treatment study results at ObesityWeek 2026, running November 14-17 in Washington, D.C. \* Phase 2 results showed investigational EloraTZP reduced weight and improved blood sugar control in adults with obesity or overweight and type 2 diabetes. \* Phase 3 trials showed investigational retatrutide reduced obstructive sleep apnea severity and knee osteoarthritis pain in adults with obesity or overweight. \* Zepbound reduced body mass index in adolescents with obesity; more than half no longer met obesity criteria. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611141201PR\_NEWS\_USPR\_\_\_\_\_DE96941) on November 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md)
- [ELIS.US](https://longbridge.com/en/quote/ELIS.US.md)
- [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md)
- [LLYZ.US](https://longbridge.com/en/quote/LLYZ.US.md)

## Related News & Research

- [BREAKINGVIEWS-Eli Lilly’s $1.4 trln valuation is heavy with hope](https://longbridge.com/en/news/305915497.md)
- [Lilly’s Zepbound shows promise in teen obesity trial](https://longbridge.com/en/news/305586139.md)
- [Eli Lilly (LLY) Stock Looks Reasonable After Its Very Large Five Year Run](https://longbridge.com/en/news/305236783.md)
- [Lilly says its obesity drugs helped patients lose weight in clinical trials](https://longbridge.com/en/news/305552284.md)
- [Stipple Bio Enters Multi-Target Oncology Collaboration With Eli Lilly](https://longbridge.com/en/news/305722464.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**